Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

Alessandro Villa, DDS, PhD, MPH, & Sook Bin Woo, DMD, MMSc  |  Issue: October 2015  |  October 13, 2015

Infections, such as periodontal disease and periapical periodontitis, are other known risk factors.46 Periodontal disease-related bacteria have been isolated from necrotic bone in 53% of MRONJ patients; these include Prevotella, Porphyromonas, Fusobacterium, Peptostreptococcus, Streptococcus sp and Eikenella.47 The presence of these bacteria and their relationship with MRONJ remain unclear. Infections are common in the oral cavity, and only a very thin mucosal barrier separates oral bacteria from the underlying bone. This may explain why such osteonecrosis has been reported only rarely at other bony sites, such as the auditory canal and the finger, and even then, always with concomitant MRONJ.48 Denture wearers are at a higher risk for MRONJ when exposed to zoledronic acid, possibly related to trauma of the denture on delicate mucosa (OR = 4.9).49 MRONJ seems to be more prevalent in women, most likely because of the higher prevalence of the underlying condition for which they receive bisphosphonates (e.g., osteoporosis and metastatic breast cancer). Corticosteroid use has also been associated with an increased risk for MRONJ.46,50

Clinical Findings & Diagnosis

The American Association of Oral and Maxillofacial Surgery (AAOMS) defines MRONJ on the basis of three criteria:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Current or previous treatment with anti-resorptive or anti-angiogenic agents;
  2. Exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for longer than eight weeks; and
  3. No history of radiation therapy to the jaws or obvious metastatic disease to the jaws.

Patients present with non-healing extraction sockets with exposed bone, or exposed bone on the mylohyoid ridge, tori, exostoses or elsewhere (see Figures 1 & 2). The mandible is involved more often than the maxilla (73% vs. 22.5%), and patients experience jaw pain in 64–82% of cases.50,51 Some patients may also develop traumatic ulcers of the tongue from sharp bone edges.

According to the AAOMS, MRONJ is classified into five stages (see Table 1).5 Many maxillary lesions readily become Stage 3, because the posterior teeth lie very close to the sinus, separated only by a thin plate of bone that is easily breached by MRONJ (see Figures 3A–B).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

If one presumes that many cases of MRONJ start deep within the bone (osteonecrosis of the jaw, bisphosphonate osteonecrosis of the jaw, bisphosphonate-related osteonecrosis of the jaws and anti-resorptive osteonecrosis of the jaws), exposure of bone is a late stage of this condition. As such, a Stage 0 form of MRONJ (sometimes referred to as non-exposed MRONJ) is recognized where there is no exposed bone, but clinical findings strongly suggest the presence of intra-bony MRONJ, such as extremely loose teeth, sinus tracts, pain disproportionate to the degree of dental disease present, and radiographic findings of moth-eaten bone and sequestra.52 This may involve 14–29% of cases.51,53

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:Conditions Tagged with:ClinicalOsteonecrosispatient carerheumatologyrhuematologist

Related Articles
    BlurryMe / shutterstock.com

    The Prevention & Management of Medication-Related Osteonecrosis of the Jaw

    March 15, 2021

    Medication-related osteonecrosis of the jaw (MRONJ) is a con­dition that manifests as exposed, necrotic and non-healing jaw bone in patients who have been treated with bisphosphonates, denosumab, chemotherapeutic agents, anti-angiogenic drugs, tyrosine kinase inhibitors, thalidomide and steroids.1-4 These medications are admin­istered via intravenous, subcutaneous and oral routes to manage osteopenia; osteoporosis; hypercalcemia of malignancy; bone…

    Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw

    December 12, 2022

    A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.

    Reading Rheum

    May 1, 2009

    Handpicked Reviews of Contemporary Literature

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    May 13, 2021

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences